Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for the maintenance treatment of opioid dependence. The drug should be used as part of a comprehensive treatment plan,
Both the firms have not disclosed the details of the agreement, under which AOP Orphan has agreed to specific annual commercial goals for AGGRASTAT. The deal will see
The Bari site, which is within Merck Serono’s global biotech production network, is part of fill & finish operations alongside the facilities in Darmstadt and Aubonne (Switzerland). The
At present, Entyvio is approved for inducing and maintaining clinical response and remission, improving endoscopic appearance of the mucosa. The drug secured the approval to achieve corticosteroid-free remission
The ORCHARRD trial failed to meet its primary endpoint as there was no statistically significant difference in progression free survival (PFS) between the treatment arms. GSK said that
It is the first patent granted for Zestra in Canada and is valid until June 2021, while it is the tenth patent that the company’s wholly-owned subsidiary, Semprae
As part of the deal, Ophthotech will receive an immediate payment of an upfront fee of $200m plus potential future recruitment and other milestone payments. Additionally, Ophthotech is
The partnership will build advanced value in Takeda’s operations by consolidating IT platforms across the organization. Under the deal, Wipro will build and maintain a global platform for
Primary liver cancer (hepatocellular carcinoma) is a particularly aggressive cancer resistant to chemotherapy treatments. Hepatocellular carcinoma represents the second leading cause of cancer-related deaths worldwide and it has
Elotuzumab is being co-developed with AbbVie, while BMS is leading the commercialization of the agent. The drug was granted this designation for use in combination with lenalidomide and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.